Stay updated on Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial

Sign up to get notified when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:27:56.000Z thumbnail image
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the efficacy or safety/tolerability evaluation of tildrakizumab (SCH 900222/MK-3222) in participants with moderate-to-severe chronic plaque psoriasis in a clinical trial setting.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:58.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying conditions such as a clinical diagnosis of moderate-to-severe plaque psoriasis and requirements for premenopausal female participants. Previously, no information was provided under Participation Criteria for Collaborators and Investigators.
    Difference
    17%
    Check dated 2024-05-22T21:28:02.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:34:04.000Z thumbnail image

Stay in the know with updates to Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.